BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 22306204)

  • 1. Myxoma virus-mediated oncolysis of ascites-derived human ovarian cancer cells and spheroids is impacted by differential AKT activity.
    Correa RJ; Komar M; Tong JG; Sivapragasam M; Rahman MM; McFadden G; Dimattia GE; Shepherd TG
    Gynecol Oncol; 2012 May; 125(2):441-50. PubMed ID: 22306204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of AKT activity is associated with reversible dormancy in ascites-derived epithelial ovarian cancer spheroids.
    Correa RJ; Peart T; Valdes YR; DiMattia GE; Shepherd TG
    Carcinogenesis; 2012 Jan; 33(1):49-58. PubMed ID: 22045027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BMP signalling controls the malignant potential of ascites-derived human epithelial ovarian cancer spheroids via AKT kinase activation.
    Peart TM; Correa RJ; Valdes YR; Dimattia GE; Shepherd TG
    Clin Exp Metastasis; 2012 Apr; 29(4):293-313. PubMed ID: 22249415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of AKT inhibition with autophagy blockade effectively reduces ascites-derived ovarian cancer cell viability.
    Correa RJ; Valdes YR; Peart TM; Fazio EN; Bertrand M; McGee J; Préfontaine M; Sugimoto A; DiMattia GE; Shepherd TG
    Carcinogenesis; 2014 Sep; 35(9):1951-61. PubMed ID: 24562574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TGFβ signaling regulates epithelial-mesenchymal plasticity in ovarian cancer ascites-derived spheroids.
    Rafehi S; Ramos Valdes Y; Bertrand M; McGee J; Préfontaine M; Sugimoto A; DiMattia GE; Shepherd TG
    Endocr Relat Cancer; 2016 Mar; 23(3):147-59. PubMed ID: 26647384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intact LKB1 activity is required for survival of dormant ovarian cancer spheroids.
    Peart T; Ramos Valdes Y; Correa RJ; Fazio E; Bertrand M; McGee J; Préfontaine M; Sugimoto A; DiMattia GE; Shepherd TG
    Oncotarget; 2015 Sep; 6(26):22424-38. PubMed ID: 26068970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mesothelial cells interact with tumor cells for the formation of ovarian cancer multicellular spheroids in peritoneal effusions.
    Matte I; Legault CM; Garde-Granger P; Laplante C; Bessette P; Rancourt C; Piché A
    Clin Exp Metastasis; 2016 Dec; 33(8):839-852. PubMed ID: 27612856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting human medulloblastoma: oncolytic virotherapy with myxoma virus is enhanced by rapamycin.
    Lun XQ; Zhou H; Alain T; Sun B; Wang L; Barrett JW; Stanford MM; McFadden G; Bell J; Senger DL; Forsyth PA
    Cancer Res; 2007 Sep; 67(18):8818-27. PubMed ID: 17875723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treating brain tumor-initiating cells using a combination of myxoma virus and rapamycin.
    Zemp FJ; Lun X; McKenzie BA; Zhou H; Maxwell L; Sun B; Kelly JJ; Stechishin O; Luchman A; Weiss S; Cairncross JG; Hamilton MG; Rabinovich BA; Rahman MM; Mohamed MR; Smallwood S; Senger DL; Bell J; McFadden G; Forsyth PA
    Neuro Oncol; 2013 Jul; 15(7):904-20. PubMed ID: 23585629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute myeloid leukemia targeting by myxoma virus in vivo depends on cell binding but not permissiveness to infection in vitro.
    Madlambayan GJ; Bartee E; Kim M; Rahman MM; Meacham A; Scott EW; McFadden G; Cogle CR
    Leuk Res; 2012 May; 36(5):619-24. PubMed ID: 22341701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting gallbladder cancer: oncolytic virotherapy with myxoma virus is enhanced by rapamycin in vitro and further improved by hyaluronan in vivo.
    Weng M; Gong W; Ma M; Chu B; Qin Y; Zhang M; Lun X; McFadden G; Forsyth P; Yang Y; Quan Z
    Mol Cancer; 2014 Apr; 13():82. PubMed ID: 24725816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metastatic Voyage of Ovarian Cancer Cells in Ascites with the Assistance of Various Cellular Components.
    Uno K; Iyoshi S; Yoshihara M; Kitami K; Mogi K; Fujimoto H; Sugiyama M; Koya Y; Yamakita Y; Nawa A; Kanayama T; Tomita H; Enomoto A; Kajiyama H
    Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spatial and temporal epithelial ovarian cancer cell heterogeneity impacts Maraba virus oncolytic potential.
    Tong JG; Valdes YR; Sivapragasam M; Barrett JW; Bell JC; Stojdl D; DiMattia GE; Shepherd TG
    BMC Cancer; 2017 Aug; 17(1):594. PubMed ID: 28854921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Re-purposing of curcumin as an anti-metastatic agent for the treatment of epithelial ovarian cancer: in vitro model using cancer stem cell enriched ovarian cancer spheroids.
    He M; Wang D; Zou D; Wang C; Lopes-Bastos B; Jiang WG; Chester J; Zhou Q; Cai J
    Oncotarget; 2016 Dec; 7(52):86374-86387. PubMed ID: 27863439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence for differential viral oncolytic efficacy in an in vitro model of epithelial ovarian cancer metastasis.
    Tong JG; Valdes YR; Barrett JW; Bell JC; Stojdl D; McFadden G; McCart JA; DiMattia GE; Shepherd TG
    Mol Ther Oncolytics; 2015; 2():15013. PubMed ID: 27119108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SMIFH2-mediated mDia formin functional inhibition potentiates chemotherapeutic targeting of human ovarian cancer spheroids.
    Ziske MA; Pettee KM; Khaing M; Rubinic K; Eisenmann KM
    Biochem Biophys Res Commun; 2016 Mar; 472(1):33-9. PubMed ID: 26898799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RNA Helicase A/DHX9 Forms Unique Cytoplasmic Antiviral Granules That Restrict Oncolytic Myxoma Virus Replication in Human Cancer Cells.
    Rahman MM; Gutierrez-Jensen AD; Glenn HL; Abrantes M; Moussatche N; McFadden G
    J Virol; 2021 Jun; 95(14):e0015121. PubMed ID: 33952639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methods for the Construction of Recombinant Oncolytic Myxoma Viruses.
    Torres-Domínguez LE; de Matos AL; Rahman MM; McFadden G
    Methods Mol Biol; 2021; 2225():63-75. PubMed ID: 33108657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ex vivo virotherapy with myxoma virus does not impair hematopoietic stem and progenitor cells.
    Villa NY; Bais S; Chan WM; Meacham AM; Wise E; Rahman MM; Moreb JS; Rosenau EH; Wingard JR; McFadden G; Cogle CR
    Cytotherapy; 2016 Mar; 18(3):465-80. PubMed ID: 26857235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myxoma virus infection promotes NK lysis of malignant gliomas in vitro and in vivo.
    Ogbomo H; Zemp FJ; Lun X; Zhang J; Stack D; Rahman MM; McFadden G; Mody CH; Forsyth PA
    PLoS One; 2013; 8(6):e66825. PubMed ID: 23762498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.